Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer
B Lee, L Lipton, J Cohen, J Tie, AA Javed, L Li, D Goldstein, M Burge, P Cooray, A Nagrial, NC Tebbutt, B Thomson, M Nikfarjam, M Harris, A Haydon, B Lawrence, DWM Tai, K Simons, AM Lennon, CL Wolfgang Show all
Annals of Oncology | OXFORD UNIV PRESS | Published : 2019
BACKGROUND: In early-stage pancreatic cancer, there are currently no biomarkers to guide selection of therapeutic options. This prospective biomarker trial evaluated the feasibility and potential clinical utility of circulating tumor DNA (ctDNA) analysis to inform adjuvant therapy decision making. MATERIALS AND METHODS: Patients considered by the multidisciplinary team to have resectable pancreatic adenocarcinoma were enrolled. Pre- and post-operative samples for ctDNA analysis were collected. PCR-based-SafeSeqS assays were used to identify mutations at codon 12, 13 and 61 of KRAS in the primary pancreatic tumor and to detect ctDNA. Results of ctDNA analysis were correlated with CA19-9, recu..View full abstract
Awarded by National Institutes of Health (NIH)
This study was supported by National Institutes of Health (NIH) grants (CA57345, R37-CA43460, U01-CA152753 and P30-CA006973) and by the Virginia and DK Ludwig Fund for Cancer Research, the Conrad N. Hilton Foundation, the Sol Goldman Sequencing Facility at Johns Hopkins, Victorian Cancer Agency Clinical Research Fellowship (to JT), Walter & Eliza Hall Institute Hemstritch Centenary Fellowship (to BL). There are no applicable grant numbers for this funding.